Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and-2 trials

被引：0
|
作者：
Bauer, Andrea [1 ]
Schuttelaar, Marie-Louise [2 ]
Baranowski, Keith [3 ]
Plohberger, Ursula [3 ]
Sorensen, Laura [3 ]
Worm, Margitta [4 ]
机构：
[1] Tech Univ Dresden, Univ Allergy Ctr, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[2] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[3] LEO Pharm A S, Ballerup, Denmark
[4] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergy, Div Allergy & Immunol, Berlin, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
chronic hand eczema; delgocitinib; JAK;
D O I：
10.1093/bjd/ljae266.033
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
654
引用
收藏
页数：2
相关论文
共 49 条
  • [21] Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis
    Simpson, Eric
    Boguniewicz, Mark
    Eichenfield, Lawrence
    Gonzales, Mercedes E.
    Hebert, Adelaide A.
    Prajapati, Vimal H.
    Gooderham, Melinda
    Krupa, David
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [22] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Blauvelt, Andrew
    Gooderham, Melinda
    Bhatia, Neal
    Langley, Richard G.
    Schneider, Shannon
    Zoidis, John
    Kurbasic, Azra
    Armstrong, April
    Silverberg, Jonathan, I
    DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2499 - 2516
  • [23] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Andrew Blauvelt
    Melinda Gooderham
    Neal Bhatia
    Richard G. Langley
    Shannon Schneider
    John Zoidis
    Azra Kurbasic
    April Armstrong
    Jonathan I. Silverberg
    Dermatology and Therapy, 2022, 12 : 2499 - 2516
  • [24] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis
    Lebwohl, Mark
    Gooderham, Melinda J.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB93 - AB93
  • [25] Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
    Strober, Bruce
    Blauvelt, Andrew
    Warren, Richard B.
    Papp, Kim A.
    Armstrong, April W.
    Gordon, Kenneth B.
    Morita, Akimichi
    Alexis, Andrew F.
    Lebwohl, Mark
    Foley, Peter
    Kisa, Renata M.
    Colston, Elizabeth
    Wang, Tao
    Banerjee, Subhashis
    Thaci, Diamant
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (08) : 1543 - 1554
  • [26] Efficacy and safety of roflumilast cream 0.15% in adults and children aged=6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
    Simpson, Eric
    Eichenfield, Lawrence
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide
    Papp, Kim
    Prajapati, Vimal
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [27] Dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid asthma requiring treatment: Analysis from two pooled phase 3 trials (liberty ad solo 1&2)
    Beck, L. A.
    Deleuran, M.
    Guttman-Yassky, E.
    Kingo, K.
    Chen, Z.
    Graham, N. M. H.
    Pirozzi, G.
    Eckert, L.
    Gadkari, A.
    Ardeleanu, M.
    ALLERGY, 2018, 73 : 76 - 77
  • [28] Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
    Lebwohl, Mark
    Leonardi, Craig
    Griffiths, Christopher E. M.
    Prinz, Joerg C.
    Szapary, Philippe O.
    Yeilding, Newman
    Guzzo, Cynthia
    Li, Shu
    Hsu, Ming-Chun
    Strober, Bruce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (05) : 731 - 741
  • [29] Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
    Thaci, D.
    Piaserico, S.
    Warren, R. B.
    Gupta, A. K.
    Cantrell, W.
    Draelos, Z.
    Foley, P.
    Igarashi, A.
    Langley, R. G.
    Asahina, A.
    Young, M.
    Falques, M.
    Pau-Charles, I.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 323 - 334
  • [30] Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials
    Papp, Kim
    Lebwohl, Mark
    Hong, H. Chih-ho
    Kircik, Leon
    Pariser, David
    Strober, Bruce
    Krueger, Gerald
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB156 - AB156
12345